Get started
ADICET BIO INC COM USD0.0001ADICET BIO INC COM USD0.0001ADICET BIO INC COM USD0.0001

ADICET BIO INC COM USD0.0001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0HX7 trade ideas

$ACET Adicet Bio Inc Long term PT 21 and higherAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
NASDAQ:ACETLong
by BADQOMOCAWGOWLD
1
Adicet Bio. Down. ACETFirst biopharma that is about to flip in our most recent experience. Just look, this baby can't climb forever. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NASDAQ:ACETShort
by Rykin_Capital
$ACET entry PT 12.70-13 Long term Target PT 32 and higherGuggenheim Maintains Buy on Adicet Bio, Raises Price Target to $32 Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.
NASDAQ:ACETLong
by BADQOMOCAWGOWLD
Long play in ACET, entry: 10.55, target: $15.00, stop 9.70On Friday June 18, ACET was once again traded down to the support at $10. It came back strong, however, and closed near the high of the day. There was heavy volume as buyers obviously saw value at this level. If it continues up this week, preferably under volume, I would be long with targets at the $12 and $15 levels (previous resistance). A good stop level would be the 52-week low at 9.71. At target 1, the risk reward ratio isn’t great at 1.7, but it is target 2 that is the main target and have a ratio of 5.2. A stop of -8.5% can seem high but with a potential profit of 42% I think it is defendable. An alternative stop could be just below the low of June 18 (10.05). Entry: 10.55 Target 1: 12.00 (13.7%) Target 2: 15.00 (42.2%) Stop: 9.70 (-8.5%) Not seeing this as a long-term play even though analysts seem to like it. The average price target according to Yahoo Finance is $28.29. If that level is in the cards, then getting in at $10 would be a good deal. However, there have been lots of insider selling and no buying. As late as June 15, founder and board member Jakobovits Aya, sold another 3,847 shares. This is a trade idea and not a recommendation. You are responsible for your own trades. Never trade with money you cannot afford to lose.
NASDAQ:ACETLong
by Three_Black_Crows